Institute for Intrinsically Disordered Protein Research, The Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Curr Opin Pharmacol. 2010 Dec;10(6):782-8. doi: 10.1016/j.coph.2010.09.005.
Transcription factors (TFs) are very attractive but difficult drug targets. The difficulties come from several directions including the binding promiscuity of TFs and the intrinsically disordered nature of their binding sites, which often resemble 'protein clouds'. For a long time the targeting of proteins without defined structures was considered infeasible. Data have now emerged showing that selective blocking of specific interactions of intrinsically disordered TFs with their protein binding partners is possible. Initial hits have been optimized to increase their specificity and affinity. Several strategies have been elaborated for elucidating the mechanisms of blocking of intrinsic disorder-based protein-protein interactions. However, challenges remain in the field of drug development for 'protein clouds'; such development is still in its earliest stage.
转录因子 (TFs) 是非常有吸引力但难以成药的靶点。困难来自多个方面,包括 TFs 的结合多效性和其结合位点的固有无序性质,这些结合位点通常类似于“蛋白质云”。长期以来,人们认为针对没有明确结构的蛋白质是不可行的。现在已经有数据表明,选择性阻断固有无序 TFs 与其蛋白质结合伙伴的特定相互作用是可能的。最初的命中物已经被优化以提高其特异性和亲和力。已经制定了几种策略来阐明基于固有无序的蛋白质-蛋白质相互作用的阻断机制。然而,在“蛋白质云”的药物开发领域仍然存在挑战;该领域仍处于早期阶段。